Mutations at Positions 547–553 of Rat Glucocorticoid Receptors Reveal That hsp90 Binding Requires the Presence, but Not Defined Composition, of a Seven-amino Acid Sequence at the Amino Terminus of the Ligand Binding Domain

Sunil C. Kaul, Patrick J. Murphy, Jun Chen, Lloyd J. Brown, William B. Pratt, S. Stoney SimonsJournal of Biological Chemistry 2002 · DOI

TL;DR

This study investigates the role of a specific seven-amino acid sequence at the N-terminus of the glucocorticoid receptor's ligand-binding domain (LBD) in its interaction with the chaperone protein hsp90. The research demonstrates that the presence of this sequence, rather than its specific amino acid composition, is crucial for stable hsp90 binding, which in turn is essential for steroid binding and receptor activation.

What Problem Does This Paper Address?

The glucocorticoid receptor (GR) is a key protein in regulating gene expression in response to steroid hormones. For GR to bind its steroid ligand and initiate this process, it must first associate with the chaperone protein hsp90. This interaction is known to "open" the GR's ligand-binding cleft, making it accessible to steroids. However, the precise location and nature of the interaction site between GR and hsp90 within the LBD have been elusive. Previous work identified a seven-amino acid stretch (positions 547-553) as critical for hsp90 binding, but the question remained: is it the specific amino acids or just the presence of this region that matters for hsp90 interaction and subsequent receptor function? This paper aims to dissect the role of this seven-amino acid sequence by systematically mutating it and observing the effects on GR's interaction with hsp90 and its biological activity.

Methods

The researchers employed a combination of molecular biology and cell-based assays:

  • Site-Directed Mutagenesis: They used PCR-based techniques to introduce specific amino acid changes (point mutations and triple mutations to alanine) and even complete sequence alterations (to alanine or proline) within the seven-amino acid region (547-553) of the rat GR.
  • Chimeric Constructs: To isolate the function of the LBD, they created fusion proteins by linking the GR LBD (amino acids 547-795) to the DNA-binding domain of the GAL4 transcription factor (GAL/GR-525C) or to glutathione S-transferase (GST). This allowed them to study the LBD's properties independently of other GR domains.
  • Transactivation Assays: They measured the ability of wild-type and mutant GRs to activate gene expression in response to dexamethasone (Dex), a synthetic glucocorticoid. This was done by transfecting cells with reporter genes (luciferase) driven by hormone-responsive elements.
  • Steroid Binding Assays: They quantified the binding of radiolabeled steroid ([³H]Dex) to GRs, both in cell-free extracts (cytosols) at 0°C and in intact living cells at 37°C.
  • Immunoprecipitation and Western Blotting: These techniques were used to assess the association of GR with hsp90 and hsp70. GR was immunoprecipitated using an anti-GR antibody, and then the presence of hsp90 and hsp70 in the precipitate was detected by Western blotting.
  • Reconstitution Assays: To further investigate the GR-hsp90 interaction, they stripped chaperones from GR and then reconstituted the GR-hsp90 heterocomplex using purified chaperone proteins.

Datasets

Not discussed in the paper. The study relies on experimental data generated from cell cultures and biochemical assays.

Key Insights and Ideas

  • Presence Over Sequence: The most striking finding is that the presence of the seven-amino acid sequence (547-553) is critical for stable hsp90 binding, but the specific amino acid composition within that sequence is less important. Mutating individual amino acids or even replacing the entire sequence with alanines (CAAAAAC) still allowed for hsp90 binding, albeit with varying effects on downstream functions.
  • Disconnecting hsp90 Binding from Steroid Binding: The CAAAAAC mutant, while still binding hsp90, completely lost steroid binding and transcriptional activity. This demonstrates that hsp90 binding alone is not sufficient for opening the ligand-binding cleft; the specific sequence context within the LBD is also required for this conformational change.
  • Dynamics of hsp90 Interaction: The P548A/T549A/V551A triple mutant showed a dramatic shift in its dose-response curve for transactivation, requiring much higher steroid concentrations. This phenotype, observed in whole cells but not in cell-free systems, suggests an increased rate of disassembly of the GR-hsp90 complex in vivo, leading to a shorter window for steroid access.
  • LBD Structure is Largely Maintained: Even with significant mutations in the 547-553 region, the overall structure of the LBD, as indicated by its ability to interact with coactivators like TIF2, remained largely intact. This suggests that the mutations primarily affect the interface with hsp90 and the subsequent conformational changes, rather than causing global structural collapse.

Key Results

  • Single point mutations in the 547-553 region had minimal impact on GR's total activity, induction fold, EC50, or partial agonist activity.
  • A triple mutation (P548A/T549A/V551A) shifted the EC50 for transactivation by over 300-fold to the right, indicating a significantly reduced sensitivity to steroid. This mutant also showed reduced steroid and hsp90 binding in whole cells but retained wild-type affinity in cell-free conditions.
  • Mutating the entire seven-amino acid region to CAAAAAC (CA5C) maintained hsp90 binding but eliminated steroid binding and transcriptional activity.
  • Reconstitution experiments showed that the 548/549/551 triple mutant GR could be fully restored to hsp90 binding and steroid binding activity when incubated with the purified chaperone assembly system, suggesting the defect lies in the dynamics of the interaction in vivo.

Limitations and Future Work

  • Mechanism of Disassembly: While the study suggests increased disassembly of the GR-hsp90 complex for the 548/549/551 triple mutant, the precise molecular mechanisms driving this accelerated disassembly remain to be elucidated.
  • Linking hsp90 Binding to Cleft Opening: The CA5C and PA5C mutants, which bind hsp90 but not steroid, provide a valuable starting point for future research. Identifying specific amino acid replacements within this region that can restore the link between hsp90 binding and the opening of the steroid-binding cleft is a key future direction.
  • Antisteroid Therapy Implications: The authors note that understanding factors modulating the partial agonist activity of antisteroids could lead to therapies with fewer side effects. The observed effects of mutations on partial agonist activity warrant further investigation in this context.
  • Role of Other GR Domains: While chimeric constructs helped isolate LBD function, the full-length GR context is still important. Further exploration of how other GR domains might influence the dynamics of the hsp90 interaction could be beneficial.

Summary updated

Abstract

Glucocorticoid receptors (GRs) must heterocomplex with hsp90 to have an open steroid binding cleft that can be accessed by steroid. We reported that a seven-amino acid sequence (547-553 of rat GR) overlapping the amino-terminal end of the ligand binding domain is required for hsp90 binding to GR. We have now conducted saturation mutagenesis of this sequence, which appears to be part of the surface where the ligand binding cleft merges with the surface of the ligand binding domain. No single point mutation causes significant changes in any of a variety of biochemical and biological properties in addition to hsp90 binding. A triple mutation (P548A/T549A/V551A) increases by >100-fold the steroid concentration required for half-maximal induction without affecting the level of maximal induction or coactivator response. Interestingly, this triple mutant displays reduced binding of steroid and hsp90 in whole cells, but it possesses wild type affinity for steroid and normal hsp90 binding capacity under cell-free conditions. This phenotype of a dramatic shift in the dose response for transactivation would be expected from an increase in the rate of disassembly of the triple mutant GR.hsp90 heterocomplex in the cell. Mutation of the entire seven-amino acid region to CAAAAAC maintains the presence of a critical alpha-helical structure and heterocomplex formation with hsp90 but eliminates steroid binding and transcriptional activation, thus disconnecting hsp90 binding from opening of the ligand binding cleft and steroid binding.
BibTeX
@article{kaul2002mutations,
  author = {Sunil C. Kaul and Patrick J. Murphy and Jun Chen and Lloyd J. Brown and William B. Pratt and S. Stoney Simons},
  title = {{Mutations at Positions 547–553 of Rat Glucocorticoid Receptors Reveal That hsp90 Binding Requires the Presence, but Not Defined Composition, of a Seven-amino Acid Sequence at the Amino Terminus of the Ligand Binding Domain}},
  journal = {Journal of Biological Chemistry},
  year = {2002},
  doi = {10.1074/jbc.m206748200},
}
Figure